February 17, 2017: Fluor Corp reports Q4 EPS of $0.82 versus the $0.80 estimate. Revenue also beat coming in at $4.99 billion versus the $4.83 billion estimate.
David Thomas Seaton, CEO of Fluor, said, “In 2016 we set the foundation to expand our presence in the markets we serve. This includes our acquisition of (Read More….)
January 10, 2017: Novo Nordisk A/S B announces marketing authorization granted by European Commission for Fiasp for treatment of diabetes in adults. Novo Nordisk expects to launch Fiasp in the first European countries in the first half of 2017. The authorisation covers all 28 European Union member states.
Fiasp is the brand name for fast-acting (Read More….)